Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human c-MET / HGFR Protein, His Tag, 1mg  

Recombinant human c-MET / HGFR Protein, His Tag, 1mg

Recombinant Human HGFR / c-MET Protein (rhHGFR) Glu 25 - Thr 932 produced in human 293 cells (HEK293), His Tag

Synonym
recombinant human protein, MET, AUTS9, HGFR, RCCP2, c-Met

More details

MET-H5227-1K

Availability: within 7 days

1 440,00 €

Background
Hepatocyte growth factor receptor (HGFR), also known as mesenchymal-epithelial transition factor (MET), c-Met, is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis [1-4].

Source
Recombinant Human HGFR /c-MET Protein (rhHGFR) Glu 25 - Thr 932 (Accession # AAI30421.1) was produced in human 293 cells (HEK293)

Molecular Characterization
rhHGFR is fused with a polyhistidine tag at the C-terminal. The mature form of HGFR is a disulfide-linked heterodimer composed of proteolytically cleaved ˞ and ˟ chain. Each ˞ and ˟ chain has a calculated MW of 32.5 kDa (˞ chain) and 60 kDa (˟ chain). The predicted N-terminal is Glu25 (˞ chain) & Ser308 (˟ chain). Protein migrates as 45 kDa (˞ chain) and 85-90 kDa (˟ chain) in reduced SDS-PAGE resulting from glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhHGFR by the LAL method.

Purity
>95% as determined by SDS-PAGE. The purity of rhHGFR was determined by reduced SDS-PAGE and staining overnight with Coomassie Blue.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4C-8C); After reconstitution under sterile conditions for 1 month (4C-8C) or 3 months (-20C to -70C).

Bioactivity
Immobilized Human HGF/Hepatocyte Growth Factor at 5μg/mL (100 μL/well) can bind Human HGF R, His Tag (Catalog # MET-H5227) with a linear range of 5-78 ng/mL.

References

(1) Bottaro DP, et al., 1991, Science 251 (4995): 802–4.
(2) Galland F, et al., 1992, Cytogenet. Cell Genet. 60 (2): 114–6.
(3) Cooper CS, 1992, Oncogene 7 (1): 3–7.
(4) Gentile A, et al., 2008, Cancer Metastasis Rev. 27 (1): 85–94.